N-Boc-L-tyrosine
Need Assistance?
  • US & Canada:
    +
  • UK: +

N-Boc-L-tyrosine

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

N-Boc-L-tyrosine is an N-Boc-protected form of L-Tyrosine.

Category
BOC-Amino Acids
Catalog number
BAT-002815
CAS number
3978-80-1
Molecular Formula
C14H19NO5
Molecular Weight
281.30
N-Boc-L-tyrosine
IUPAC Name
(2S)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
Synonyms
N-[(1,1-Dimethylethoxy)carbonyl]-L-tyrosine; N-Carboxy-L-tyrosine N-tert-Butyl Ester; (2S)-2-[(tert-Butoxycarbonyl)amino]-3-(4-hydroxyphenyl)propanoic Acid; (2S)-2-[(tert-Butoxycarbonyl)amino]-3-(4-hydroxyphenyl)propanoic Acid; BOC-L-tyrosine; N-(tert-Butoxycarbonyl)tyrosine; N-(tert-Butyloxycarbonyl)-L-tyrosine; N-tert-Butoxycarbonyl-L-tyrosine; NSC 334307; tert-Butoxycarbonyl-L-tyrosine
Appearance
White to Off-white Solid
Purity
≥98% by HPLC
Density
1.1755 g/cm3
Melting Point
278-280°C (dec.)
Boiling Point
423.97°C
Storage
2-8 °C
Solubility
Soluble in DMSO (Slightly), Methanol (Sparingly)
InChI
InChI=1S/C14H19NO5/c1-14(2,3)20-13(19)15-11(12(17)18)8-9-4-6-10(16)7-5-9/h4-7,11,16H,8H2,1-3H3,(H,15,19)(H,17,18)/t11-/m0/s1
InChI Key
CNBUSIJNWNXLQQ-NSHDSACASA-N
Canonical SMILES
CC(C)(C)OC(=O)NC(CC1=CC=C(C=C1)O)C(=O)O
1. Design, synthesis, in vitro, in vivo and in silico pharmacological characterization of antidiabetic N-Boc-l-tyrosine-based compounds
Miguel Ángel Herrera-Rueda, et al. Biomed Pharmacother. 2018 Dec;108:670-678. doi: 10.1016/j.biopha.2018.09.074. Epub 2018 Sep 21.
In this study, we synthesized five N-Boc-L-tyrosine-based analogues to glitazars. The in vitro effects of compounds 1-5 on protein tyrosine phosphatase 1B (PTP-1B), peroxisome proliferator-activated receptor alpha and gamma (PPARα/γ), glucose transporter type-4 (GLUT-4) and fatty acid transport protein-1 (FATP-1) activation are reported in this paper. Compounds 1 and 3 were the most active in the in vitro PTP-1B inhibition assay, showing IC50s of approximately 44 μM. Treatment of adipocytes with compound 1 increased the mRNA expression of PPARγ and GLUT-4 by 8- and 3-fold, respectively. Moreover, both compounds (1 and 3) also increased the relative mRNA expression of PPARα (by 8-fold) and FATP-1 (by 15-fold). Molecular docking studies were performed in order to elucidate the polypharmacological binding mode of the most active compounds on these targets. Finally, a murine model of hyperglycemia was used to evaluate the in vivo effectiveness of compounds 1 and 3. We found that both compounds are orally active using an exploratory dose of 100 mg/kg, decreasing the blood glucose concentration in an oral glucose tolerance test and a non-insulin-dependent diabetes mellitus murine model. In conclusion, we demonstrated that both molecules showed strong in vitro and in vivo effects and can be considered polypharmacological antidiabetic candidates.
2. Affinity analysis and application of dipeptides derived from l-tyrosine in plasmid purification
Soraia Ferreira, Josué Carvalho, Joana F A Valente, Marta C Corvo, Eurico J Cabrita, Fani Sousa, João A Queiroz, Carla Cruz J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Dec 1;1006:47-58. doi: 10.1016/j.jchromb.2015.10.025. Epub 2015 Oct 23.
The developments in the use of plasmid DNA (pDNA) in gene therapy and vaccines have motivated the search and improvement of optimized purification processes. In this context, dipeptides l-tyrosine-l-tyrosine and l-tyrosine-l-arginine are synthetized to explore their application as affinity ligands for supercoiled (sc) plasmid DNA (pDNA) purification. The synthesis is based on the protection of N-Boc-l-tyrosine, followed by condensation with l-tyrosine or l-arginine methyl esters in the presence of dicyclohexylcarbodiimide (DCC), which after hydrolysis and acidification give the afforded dipeptides. The supports are then obtained by coupling l-tyrosine, l-tyrosine-l-tyrosine and l-tyrosine-l-arginine to epoxy-activated Sepharose and are characterized by high resolution magic angle spinning (HR-MAS) NMR and Fourier transform infrared spectroscopy (FTIR). Surface plasmon resonance (SPR) biosensor is used to establish the promising ligand to be used in the chromatographic experiments and ascertain experimental conditions. Sc isoform showed the highest affinity to the dipeptides, followed by linear (ln) pDNA, being the open circular (oc) the one that promoted the lowest affinity to l-tyrosine-l-arginine. Saturation transfer difference (STD)-NMR experiments show that the interaction is mainly hydrophobic with the majority of the 5'-mononucleotides, except for 5'-GMP with l-tyrosine-l-arginine Sepharose that is mainly electrostatic. The support l-tyrosine Sepharose used in chromatographic experiments promotes the separation of native pVAX1-LacZ and pcDNA3-FLAG-p53 samples (oc+sc) by decreasing the salt concentration. The results suggest that it is possible to purify different plasmids with the l-tyrosine Sepharose, with slight adjustments in the gradient conditions.
3. A dityrosine-based substrate for a protease assay: application for the selective assessment of papain and chymopapain activity
Chan-Jin Kim, Dong-Ik Lee, Chang-Ha Lee, Ik-Sung Ahn Anal Chim Acta. 2012 Apr 20;723:101-7. doi: 10.1016/j.aca.2012.02.038. Epub 2012 Feb 27.
N,N'-diBoc-dityrosine (DBDY), which was synthesized by the oxidative C-C coupling of 2 N-Boc-L-tyrosine molecules, was conjugated with two isoniazid (INH) molecules. Due to the quenching effect of INH, DBDY-(INH)(2) lacks the fluorescence of DBDY. As such, it was tested for use in the detection of proteases by measuring fluorescence recovery. In this study, serine proteases (chymotrypsin, trypsin, subtilisin, and proteinase K), metalloproteases (thermolysin and carboxypeptidase A, dispase, and collagenase), aspartic proteases (pepsin and aspergillopepsin) and cysteine proteases (papain and chymopapain) were chosen. Reported optimum assay conditions were chosen for each enzyme. Only papain and chymopapain catalyzed the hydrolysis of DBDY-(INH)(2) and led to fluorescence recovery, possibly due to their extensive binding sites and the INH-mediated inhibition of metalloproteases and aspartic proteases.
Online Inquiry
Verification code
Inquiry Basket